Upregulation of 15 antisense long non-coding rnas in osteosarcoma

Emel Rothzerg; Xuan Dung Ho; Jiake Xu; David Wood; Aare Märtson; Sulev Kõks

doi:10.3390/genes12081132

Upregulation of 15 antisense long non-coding rnas in osteosarcoma

Emel Rothzerg, Xuan Dung Ho, Jiake Xu, David Wood, Aare Märtson, Sulev Kõks

Research output: Contribution to journal › Article › peer-review

33 Citations (Web of Science)

Abstract

The human genome encodes thousands of natural antisense long noncoding RNAs (lncR-NAs); they play the essential role in regulation of gene expression at multiple levels, including replication, transcription and translation. Dysregulation of antisense lncRNAs plays indispensable roles in numerous biological progress, such as tumour progression, metastasis and resistance to therapeutic agents. To date, there have been several studies analysing antisense lncRNAs expression profiles in cancer, but not enough to highlight the complexity of the disease. In this study, we investigated the expression patterns of antisense lncRNAs from osteosarcoma and healthy bone samples (24 tumour-16 bone samples) using RNA sequencing. We identified 15 antisense lncRNAs (RUSC1-AS1, TBX2-AS1, PTOV1-AS1, UBE2D3-AS1, ERCC8-AS1, ZMIZ1-AS1, RNF144A-AS1, RDH10-AS1, TRG-AS1, GSN-AS1, HMGA2-AS1, ZNF528-AS1, OTUD6B-AS1, COX10-AS1 and SLC16A1-AS1) that were upregulated in tumour samples compared to bone sample controls. Further, we performed real-time polymerase chain reaction (RT-qPCR) to validate the expressions of the antisense lncRNAs in 8 different osteosarcoma cell lines (SaOS-2, G-292, HOS, U2-OS, 143B, SJSA-1, MG-63, and MNNG/HOS) compared to hFOB (human osteoblast cell line). These differentially expressed IncRNAs can be considered biomarkers and potential therapeutic targets for osteosarcoma.

Original language	English
Article number	1132
Journal	Genes
Volume	12
Issue number	8
DOIs	https://doi.org/10.3390/genes12081132
Publication status	Published - Aug 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/genes12081132Licence: CC BY

Cite this

@article{658f4f78800b4a3cbf93986fcb7cbc6e,

title = "Upregulation of 15 antisense long non-coding rnas in osteosarcoma",

abstract = "The human genome encodes thousands of natural antisense long noncoding RNAs (lncR-NAs); they play the essential role in regulation of gene expression at multiple levels, including replication, transcription and translation. Dysregulation of antisense lncRNAs plays indispensable roles in numerous biological progress, such as tumour progression, metastasis and resistance to therapeutic agents. To date, there have been several studies analysing antisense lncRNAs expression profiles in cancer, but not enough to highlight the complexity of the disease. In this study, we investigated the expression patterns of antisense lncRNAs from osteosarcoma and healthy bone samples (24 tumour-16 bone samples) using RNA sequencing. We identified 15 antisense lncRNAs (RUSC1-AS1, TBX2-AS1, PTOV1-AS1, UBE2D3-AS1, ERCC8-AS1, ZMIZ1-AS1, RNF144A-AS1, RDH10-AS1, TRG-AS1, GSN-AS1, HMGA2-AS1, ZNF528-AS1, OTUD6B-AS1, COX10-AS1 and SLC16A1-AS1) that were upregulated in tumour samples compared to bone sample controls. Further, we performed real-time polymerase chain reaction (RT-qPCR) to validate the expressions of the antisense lncRNAs in 8 different osteosarcoma cell lines (SaOS-2, G-292, HOS, U2-OS, 143B, SJSA-1, MG-63, and MNNG/HOS) compared to hFOB (human osteoblast cell line). These differentially expressed IncRNAs can be considered biomarkers and potential therapeutic targets for osteosarcoma.",

keywords = "Alternative splicing, Antisense RNA, Non-coding RNA, Osteosarcoma, Sarcoma",

author = "Emel Rothzerg and Ho, {Xuan Dung} and Jiake Xu and David Wood and Aare M{\"a}rtson and Sulev K{\~o}ks",

year = "2021",

month = aug,

doi = "10.3390/genes12081132",

language = "English",

volume = "12",

journal = "Genes",

issn = "2073-4425",

publisher = "MDPI AG",

number = "8",

}

TY - JOUR

T1 - Upregulation of 15 antisense long non-coding rnas in osteosarcoma

AU - Rothzerg, Emel

AU - Ho, Xuan Dung

AU - Xu, Jiake

AU - Wood, David

AU - Märtson, Aare

AU - Kõks, Sulev

PY - 2021/8

Y1 - 2021/8

N2 - The human genome encodes thousands of natural antisense long noncoding RNAs (lncR-NAs); they play the essential role in regulation of gene expression at multiple levels, including replication, transcription and translation. Dysregulation of antisense lncRNAs plays indispensable roles in numerous biological progress, such as tumour progression, metastasis and resistance to therapeutic agents. To date, there have been several studies analysing antisense lncRNAs expression profiles in cancer, but not enough to highlight the complexity of the disease. In this study, we investigated the expression patterns of antisense lncRNAs from osteosarcoma and healthy bone samples (24 tumour-16 bone samples) using RNA sequencing. We identified 15 antisense lncRNAs (RUSC1-AS1, TBX2-AS1, PTOV1-AS1, UBE2D3-AS1, ERCC8-AS1, ZMIZ1-AS1, RNF144A-AS1, RDH10-AS1, TRG-AS1, GSN-AS1, HMGA2-AS1, ZNF528-AS1, OTUD6B-AS1, COX10-AS1 and SLC16A1-AS1) that were upregulated in tumour samples compared to bone sample controls. Further, we performed real-time polymerase chain reaction (RT-qPCR) to validate the expressions of the antisense lncRNAs in 8 different osteosarcoma cell lines (SaOS-2, G-292, HOS, U2-OS, 143B, SJSA-1, MG-63, and MNNG/HOS) compared to hFOB (human osteoblast cell line). These differentially expressed IncRNAs can be considered biomarkers and potential therapeutic targets for osteosarcoma.

AB - The human genome encodes thousands of natural antisense long noncoding RNAs (lncR-NAs); they play the essential role in regulation of gene expression at multiple levels, including replication, transcription and translation. Dysregulation of antisense lncRNAs plays indispensable roles in numerous biological progress, such as tumour progression, metastasis and resistance to therapeutic agents. To date, there have been several studies analysing antisense lncRNAs expression profiles in cancer, but not enough to highlight the complexity of the disease. In this study, we investigated the expression patterns of antisense lncRNAs from osteosarcoma and healthy bone samples (24 tumour-16 bone samples) using RNA sequencing. We identified 15 antisense lncRNAs (RUSC1-AS1, TBX2-AS1, PTOV1-AS1, UBE2D3-AS1, ERCC8-AS1, ZMIZ1-AS1, RNF144A-AS1, RDH10-AS1, TRG-AS1, GSN-AS1, HMGA2-AS1, ZNF528-AS1, OTUD6B-AS1, COX10-AS1 and SLC16A1-AS1) that were upregulated in tumour samples compared to bone sample controls. Further, we performed real-time polymerase chain reaction (RT-qPCR) to validate the expressions of the antisense lncRNAs in 8 different osteosarcoma cell lines (SaOS-2, G-292, HOS, U2-OS, 143B, SJSA-1, MG-63, and MNNG/HOS) compared to hFOB (human osteoblast cell line). These differentially expressed IncRNAs can be considered biomarkers and potential therapeutic targets for osteosarcoma.

KW - Alternative splicing

KW - Antisense RNA

KW - Non-coding RNA

KW - Osteosarcoma

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85111753532&partnerID=8YFLogxK

U2 - 10.3390/genes12081132

DO - 10.3390/genes12081132

M3 - Article

C2 - 34440306

AN - SCOPUS:85111753532

SN - 2073-4425

VL - 12

JO - Genes

JF - Genes

IS - 8

M1 - 1132

ER -

Upregulation of 15 antisense long non-coding rnas in osteosarcoma

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Integrating bioinformatics and molecular biology to identify novel genetic markers and treatment targets for osteosarcoma

Cite this